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Myocardial infarction (MI), often referred to as a heart attack, is a serious health issue in 
the United States.  There is a well-documented link between MI and major depressive disorder 
(MDD), with a high incidence of MDD occurring after an MI.  Overlapping pathologies have 
been observed within the hippocampus of the brain in animal models of MI and depression.  
These observations suggest that pathobiological cross-talk between the heart and brain could 
have a role in the etiology of MDD that occurs after an MI.  Spinal cord stimulation (SCS) has 
previously been shown to have both cardioprotective and neuroprotective effects post-MI, and 
hence may protect individuals from developing depression post-MI.  In this study, we examined 
the potential biochemical mechanisms that might underlie the neuroprotective actions of SCS 
following MI.  Brain tissues were obtained from three groups of canines: sham-operated animals, 
animals subjected to experimental myocardial infarction/mitral regurgitation (MI/MR), and 
animals subjected to MI/MR that were simultaneously administered SCS.  The whole 
hippocampus and hippocampal dentate gyrus were dissected from frozen brains.  Quantitative 
endpoint-PCR and RT-qPCR techniques were employed to measure select biochemical 
mediators of neuroprotection, i.e. adenosine A2A receptor, ghrelin, and ghrelin receptor 
expression in hippocampal samples.  SCS induced a significant decrease in A2A receptor 
expression and a dramatic increase in ghrelin expression in MI/MR canines as compared to the 
MI/MR group without SCS. These findings suggest that adenosine receptors and ghrelin may 
play a biochemical role in SCS-induced neuroprotection of the hippocampus. Understanding the 
neuroprotective actions of SCS has the potential to aid the development of new treatments or 
preventative measures for depression following a heart attack.  
  




Myocardial infarction (MI), commonly known as a heart attack, is a serious health issue 
in major industrialized countries with over two million people in the United States hospitalized 
with MIs between 2000 and 2008 (47).  Of these patients, 65% are estimated to experience 
depressive symptoms and 20% will develop major depressive disorder (MDD) (49). Conversely, 
MDD has been linked with an increased risk of an MI, and patients with MDD have a fourfold 
increase in risk of death after an MI compared to those without depression (8). These clinical 
observations provide evidence for pathobiological cross-talk between the brain and the heart. 
Despite significant research in the field, the pathophysiological and biochemical link between MI 
and MDD remains poorly understood. However, several morphological and biochemical changes 
have been observed in experimental animal models following experimentally induced MI (17), 
including apoptosis in the amygdala and hippocampus (13, 48, 49). These two brain regions are 
part of the limbic system, a part of the brain that deals with emotion, and are known to play a 
distinct role in the pathobiology of depression (37).  Hence, these brain regions are prime 
suspects for the study of pathobiological processes that may contribute to the linkage between 
MDD and MI.   
During an MI, the damaged myocardium causes an increase in serum levels of purine 
nucleotides, including adenosine (1).  Adenosine, a metabolite of adenosine triphosphate and a 
natural ligand of the adenosine receptor, is an endogenous cardioprotective agent that reduces the 
severity of ischemia and reperfusion injury (30).  Previous research has linked adenosine 
imbalance to MDD, but studies have shown conflicting results (12). Adenosine binds to four 
different receptor subtypes, each with a different function and encoded by a separate gene. The 
subtype of interest in this thesis is the A2A receptor, because A2A receptors play a role in the heart 
by regulating blood flow and myocardial oxygen consumption (31) and have broader anti-
inflammatory effects throughout the body (43). The A2A receptor is extensively expressed within 
the hippocampus and in brain endothelial cells that comprise the blood brain barrier (BBB) (43, 
38). Adenosine can increase the permeability of the BBB by binding to A2A receptors on brain 
endothelial cells. Administration of an A2A receptor agonist has been shown to increase BBB 
permeability enough to allow proteins up to 70 kDa in size to pass through the barrier (7).  This 
increase in penetrability could allow pro-inflammatory cytokines released from the damaged area 
to enter the brain, as long as they are below 70 kDa in size.  
One inflammatory cytokines that could potentially enter the brain following A2A 
activation is tumor necrosis factor alpha (TNF-α), which has a size of 26 kDa (45).  TNF-α is an 
inflammatory cytokine that plays a major role in activation of immune cells (35). Patients 
suffering from MDD have high serum levels of several pro-inflammatory cytokines, including 
TNF-α, pointing to the involvement of an inflammatory process in the pathology of MDD (41).  
Interestingly, TNF-α participates in apoptosis in the CA1, CA3, and dentate gyrus regions of the 
hippocampus via caspase-3 and caspase-8 activation following a MI (27, 13).  
Adenosine and TNF-α have a complex signaling relationship. TNF-α increases the 
expression of adenosine A2A receptors in human epithelial cells by acting as a transcription factor 
(40). However, administration of a potent A2A receptor agonist reduces TNF-α levels and 
apoptosis in the hippocampus (5), suggesting the existence of a feedback inhibition mechanism 
whereby TNF-α increases A2A receptors, which in turn reduce the amount of TNF-α. 
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Spinal cord stimulation (SCS) is a novel treatment for patients who have experienced an 
MI. SCS belongs to a new and growing field of therapeutics referred to as “electroceuticals”. 
Electroceuticals are a class of medical devices that exert their effects via electrical modulation of 
the nervous system, or neuromodulation. In the case of SCS, a device is implanted in the patient 
that delivers electrical signals at a specified frequency to the spinal cord (46, 16). SCS works by 
modulating the existing neurochemical pathways within the autonomic nervous system (36). 
Sympatholytic effects, i.e. reducing peripheral sympathetic drive caused by MI and afferent 
sensory cardiac firing, are believed to be the primary mechanism of action of thoracic SCS (25). 
This has potential implications for depression research, as patients with MDD have shown an 
altered autonomic balance with sympathetic inputs predominating over parasympathetic inputs. 
It is believed that this is associated with both baroreflex sensitivity and heart rate variability (33). 
Despite this knowledge, the specific chemical mechanism that causes SCS’s sympatholytic 
effects remains unknown. 
Ghrelin may be involved in the biochemical mechanism of SCS-induced benefits post-
MI.  Ghrelin is a 28 amino-acid peptide that acts as an orexigenic hormone (24).  Ghrelin is 
widely expressed throughout the human body (19), being primarily expressed in the 
gastrointestinal tract.  Interestingly, ghrelin plays a distinct role within the central nervous 
system (CNS). Both ghrelin and the growth-hormone secretagogue receptor (GHSR), the only 
known ghrelin receptor, are extensively expressed throughout the CNS (20).  Ghrelin has been 
shown to be involved in several areas of CNS physiology, including cognition (4), sleep (32), 
and mood (10). Abnormalities of ghrelin and GHSR expression have been previously suggested 
to play a role in several psychiatric disorders, (schizophrenia, anorexia nervosa, anxiety, and 
MDD) as well as being involved in stress regulation (50). Factors involved in the regulation of 
both ghrelin and GHSR remain unclear.  
Intraperitoneal injection of ghrelin in rat models has been shown to improve cardiac 
function and remodeling (29) and to reduce TNF-α levels within the CNS (52). Furthermore, 
ghrelin has notable neuroprotective effects within the rat brain. Intraperitoneal ghrelin 
administration in rodent models caused upregulation of hippocampal neurogenesis, even 
independently of growth hormone and insulin-like growth factor (34). Rats injected with 
physiological doses of ghrelin have also shown significant improvement of performance on 
memory tests, which has been linked to a properly functioning hippocampus (28). Finally, serum 
ghrelin levels are increased by vagal nerve activity and reduced by sympathetic nervous system 
activity (22).  Since SCS exerts sympatholytic effects by withdrawal of sympathetic tone or 
increase of vagal tone (25), it is anticipated that SCS may increase ghrelin levels which could 
mediate at least some of the beneficial effects of SCS after MI. Interestingly, adenosine has been 
shown to stimulate ghrelin release in the mouse stomach (51), as well as serve as a partial agonist 
to the GHSR receptor within the porcine hypothalamus (44), resulting in cross-talk between the 
adenosine and ghrelin signaling systems (9). 
While previous research has shown intraperitoneal injections of ghrelin to have 
neuroprotective effects, the therapeutic potential for increasing local expression of ghrelin in the 
hippocampus has not been studied. SCS may cause an increase of local ghrelin release within the 
hippocampus, particularly since ghrelin and GHSR are widely expressed on the hippocampus 
and dentate gyrus.  If ghrelin expression were upregulated during SCS, it could potentially 
reduce TNF-α within the hippocampus, reducing post-MI apoptosis. 
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Taken together, the previous findings implicate a possible relationship between ghrelin, 
A2A receptors and TNF-α in MI and SCS. This thesis focuses on elucidating the potential 
therapeutic mechanism of SCS administered after MI by studying gene expression in the 
hippocampus from canines in a model of MI.  Expression levels of adenosine A2A receptors, 
GHSR receptors, and ghrelin were measured.  My findings provide a possible explanation for the 
neuroprotective effects of SCS after MI, and have the potential to advance the discovery of new 
treatments or preventative measures for depression following a heart attack.  
Methods 
Approval of Animal Protocol 
The use of animals in this study were approved and monitored by the Institutional Animal Care 
and Use Committee and the Division of Laboratory Animal Research. 
Heart Failure and Spinal Cord Stimulation (SCS) Models 
Three experimental groups were used in this study: 8 sham-operated control canines, 8 canines 
that had undergone a myocardial infarction and mitral regurgitation (MI/MR; a model of heart 
failure) and 6 canines that had undergone an MI/MR and SCS. For the MI/MR groups, 
myocardial infarction was created by performing 20-minute critical stenosis (~50%) on the left 
anterior descending coronary artery. After this, a 90-minute full occlusion and subsequent 
reperfusion of the left anterior coronary artery was performed. For the MI/MR + SCS group, a 
spinal cord stimulating device and pulse generator were implanted in the T1-T3 and T4-T5 levels 
of the spinal cord. The pulse generator was set on a schedule of 50 Hz, 200 µs. MR was 
produced two weeks following the MI by cutting roughly 20% of mitral valve chordae until an 
audible murmur was heard and appropriate left ventricular end diastolic pressure was met. SCS 
was activated in the SCS group one week following surgery. Canines were terminated four 
months following MI. Control canines were also maintained for four months and then terminated 
(13).  Extensive measures of cardiac function were performed on all animals as a part of a 
separate study. 
Tissue Acquisition 
After animals were terminated in the course of the cardiac function study, we obtained brain 
tissue postmortem.  Brain tissue was immediately removed to preserve RNA quality, and then 
dissected into smaller tissues in a cryostat at -20 °C. Finally, the tissues were stored at -80 °C.   
Neuropathological Assessment 
Frozen blocks of the left temporal and occipital cortex were sectioned into 50 µm sections using 
a Leica CM3050S cryostat microtome. The samples were then punched with a disposable 3.5 
mm puncher. The whole hippocampus, amygdala, and occipital cortex gray matter was collected 
for gene expression analysis. Punched tissues from the ventral hippocampus were then collected 
at relatively the same place on every animal and stored in microcentrifuge tubes at -80 °C for the 
purpose of downstream assays 
Total RNA Purification and Generation of cDNA  
Total RNA was extracted from the dentate gyrus sample using the RNAqueous Micro Kit 
(includes DNase treatment; Ambion, USA). RNA samples were then stored at -90 °C according 
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to protocols previously published (42). SuperScript III cDNA was synthesized from RNA using 
the First-Strand Synthesis SuperMix (Invitrogen, Carlsbad, CA) reverse transcriptase kit 
according to the manufacturer's recommendations. 
Primers for RT-PCR and End-Point PCR Gene Expression Assays 
Gene-specific primers were designed using the UNAFold Web Server software (53) 
(http://mfold.rna.albany.edu) for folding prediction and the Integrated DNA Technologies 
PrimerQuestSM Web Server software 
(http://www.idtdna.com/Scitools/Applications/Primerquest/). 
Primers (Table 1) were designed to have a GC content of 45–55% and to span introns to prevent 
amplification of genomic DNA. The amplification conditions for each primer and gene set were 
standardized and optimized.  
Quantitative Real-Time PCR (qPCR) 
Each cDNA sample was checked against a sample of the RNA it was reverse transcribed from by 
running an identical mock RT reaction without the reverse transcriptase enzyme added. If no 
DNA was present at the end of this reaction (RT minus control), then it was concluded that 
genomic DNA contamination was not present in the sample.  One µL of resulting cDNA was 
then used as a template for real-time PCR performed with a Stratagene MX3000P QPCR System 
(Agilent Technology, Inc., CA). Gene specific primers were used to carry out amplification at a 
final concentration of 400 nM for both reference and target genes. All quantitative PCR 
amplifications were performed, following the manufacturer’s instructions, in triplicate wells 
using Platinum Quantitative PCR SuperMix-UDG (Invitrogen, Carlsbad, CA). The quantity of 
the target gene was assessed using the cycle threshold (CT) value. The CT value was determined 
as the point at which the increased fluorescence exceeded background fluorescence, and the 
median CT value from each triplicate was used for expression analysis. For comparisons 
between sham and treated subjects, cDNAs from all canine samples were amplified 
simultaneously on the same plate.  
End-Point PCR 
End-point PCR was carried out in an Eppendorf Master Cycler ep (Eppendorf, Hamburg, 
Germany) using gene specific primers and Taq DNA Polymerase 100 U enzyme (5prime 
Technologies, Gaithersburg, MD). An Agilent Tape Station 2200 and Agilent Tape Station 2200 
screen tapes (Agilent Technologies, Santa Clara, CA) were utilized using manufacturer’s 
instructions for electrophoresis and analysis of gene amplification. The concentration [ng/µl] was 
used for gene expression analysis.  
Data Analysis 
Cycle threshold values from qPCR results were mathematically converted to ng/µl and the 
compared to expression of reference genes SuccDH and GADPH (included in supplemental 
materials). Endpoint PCR results were also compared to the same reference genes. Using these 
reference genes, relative expression values were calculated. Graphs were produced and 
significance was determined using a one-way analysis of variance (ANOVA) test with Tukey 
post-hoc analysis (PRISM GraphPad version 5), using a p-value <0.05 to determine statistical 
significance.   






Figure 1: Relative Gene Expression of A2A Receptor 
A2A receptor gene expression in the hippocampus is shown in Figure 1 for the three 
groups of canines.  SCS therapy for MI/MR animals produced a significant decrease in A2A 
receptor gene expression relative to the MI/MR group.  MI/MR increased A2A receptor gene 
expression relative to sham control animals, although the effect did not quite reach statistical 
significance (p=0.053). These data show that SCS has a negative effect on A2A expression.  
Considering the previously discussed TNF-α-A2A feedback inhibition loop, one might expect that 
SCS might also lower TNF-α expression. Future studies ought to consider directly quantifying 
the amount of TNF-α within the hippocampus. 




Figure 2: Relative Gene Expression of Ghrelin 
 Figure 2 shows the effects of MI/MR and SCS plus MI/MR on ghrelin gene expression.  
SCS significantly increased ghrelin gene expression levels in the hippocampus from MI/MR 
canines as compared to both control and untreated MI/MR canines. MI/MR alone induced a 
significant lowering of ghrelin gene expression. These data indicate that ghrelin plays a 
significant role in the actions of SCS. Additionally, expression levels of the GHSR receptor 
gene, the receptor which ghrelin binds to, where checked and no significant change was observed 
in any of the groups of canines (not shown).  




Figure 3: Relative Gene Expression of GLUT-1 
To consider the possibility that SCS produces neuroprotection after MI by preventing 
hypoxia in MI/MR animals, a gene expression marker, GLUT-1, was measured in the three 
groups of animals (Figure 3).  GLUT-1 gene expression levels suggest that canines in the MI/MR 
and MI/MR with SCS did not experience hypoxia.  
Previous PCR analysis done on oxygen sensitive (6) hypoxia inducible factor 1-α (HIF-
1α) revealed no significant difference between the three groups. However, HIF-1α is regulated at 
the protein level (18), so HIF-1α levels do not necessarily reflect a hypoxic response. To remedy 
this, expression of Glucose transporter protein type 1 (GLUT-1) was checked. GLUT-1 is a high-
affinity glucose membrane transport protein regulated at the message level by the HIF-1α 
pathway (39, 15). Hypoxic conditions encourage greater expression of GLUT-16 and GLUT-1 
has been shown to be a reliable endogenous marker of hypoxia (21, 11). 
  Results showed no significant difference in GLUT-1 expression in any of the 




It has been previously reported that SCS has cardioprotective effects. In animal models, 
SCS significantly reduced infarct size, reduced arrhythmias, and improved cardiac remodeling 
(46, 2, 3). Further research done by our lab has also given support to the hypothesis that SCS has 
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similar protective effects in the central nervous system (13). Results have indicated that MI/MR 
is associated with gross morphological deficits within the hippocampus. Our lab has also 
previously demonstrated that thoracic SCS is able to prevent the development of brain 
pathologies that could potentially contribute to the development of post-MI MDD (13).  
This thesis attempted to determine at least part of underlying mechanism of SCS’s 
neuroprotective effects. The region of interest within the brain was the hippocampus, due to its 
vital role in the limbic (emotional) system of the brain. The neuroanatomical networks between 
the hippocampus with other parts of the limbic system and also cardiovascular control centers 
have been implicated to hold a significant role in the pathology of MDD.  In particular, the 
dentate gyrus of the hippocampus’s involvement in both neurogenesis and the development of 
mood disorders following MI have made it a particular area of interest (14, 26, 23). 
The relative sensitivity of A2A receptors in the brain and the large increase in serum 
adenosine post-MI (1) made the A2A receptor an ideal candidate for study in this thesis research. 
A2A receptors are widely expressed in the hippocampus, and adenosine imbalances have 
previously been implicated in the development of MDD (12). This thesis research has shown that 
delivery of SCS to heart failure canines (modeled by MI/MR) significantly lowered A2A receptor 
gene expression levels. This not only indicates that adenosine signaling may play a role in the 
mechanism of SCS, but, due to the proposed feedback inhibition relationship between TNF-α 
and A2A receptors (5,40), may also indicate that TNF-α levels could be reduced within the 
hippocampus.  
This thesis also explored the role that ghrelin, and its receptor GHSR, may play in the 
mechanism of SCS. Ghrelin imbalances have been linked to psychological disorders, and ghrelin 
has a poorly understood role in the functioning of the CNS (50). Ghrelin would be expected to be 
released when sympathetic neuronal activity is reduced, as has been shown to occur during SCS.  
These effects make ghrelin an ideal candidate for a role in SCS’s effects (22). This thesis 
research showed ghrelin gene expression in the hippocampus was reduced by heart failure.  In 
marked contrast, SCS treatment of heart failure animals robustly increased ghrelin gene 
expression in the hippocampus. These findings strongly indicate that ghrelin plays a major role 
in the neurochemical actions of SCS in the brain, and possibly contributes specifically to the 
neuroprotective actions of SCS in the treatment of heart failure in the canine model that this 
laboratory has previously observed.  Because increasing sympathetic neuronal activity is known 
to reduce ghrelin levels, the ability of SCS to increase ghrelin gene expression lends further 
credence to the previously proposed sympatholytic mechanism of SCS. 
Finally, the expression of GLUT-1 was checked because it is an endogenous biomarker 
of hypoxia.  Hence, an increased gene expression of GLUT-1 could indicate that the positive 
effects of SCS are merely due to an improvement in circulatory health, rather than a distinct 
biochemical mechanism (21, 11). No noticeable change was detected in GLUT-1 expression in 
any experimental group, indicating that hypoxia was not a relevant factor in this study. This 
provides evidence that SCS’s mechanism of action within the brain is due to more than improved 
cardiovascular circulation.  
The results of this thesis research warrant further study of the mechanism of SCS. A 
direct measurement of TNF-α levels within the hippocampus is needed, as that would provide 
further support to the proposed role of A2A receptors and ghrelin in the central actions of SCS. 
Additionally, serum levels of adenosine and TNF-α from the canines used in this study would 
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clarify the role of adenosine signaling in MI and SCS. Finally, investigation of other factors in 
the adenosine and ghrelin signaling systems, such as the A1 receptor and leptin, would also 
contribute to a clearer understanding of SCS’s mechanism of action.  
The results of my thesis research have helped further elucidate the biochemical 
mechanisms underlying the neuroprotective effects of SCS. This thesis has shown that adenosine 
and ghrelin signaling likely play an important role in the mechanism of SCS, while effects on 
hypoxia do not. Knowledge of this mechanism could aid in the development of future treatments 
for MI and MDD, as well as provide new avenues for research into diseases that affect the 
hippocampus.   
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Supplemental Materials 
Table 1: Primers Utilized in Study 




GAPDH NC_006609.3 TGACACCCACTCTTCCACCTTCGAC 
CACCCGGTTGCTGTAGCCAAATTC 
110 68 
SDHA NC_006616.3 AATCCGTGAAGGCAGAGGCTGTGG 
GCCGTCTCTGAAATGCCAGGCAGA 
111 64 
ACTB NM_001195845             CACTATTGGCAACGAGCGGTTC 
GTAGTTTCATGGATGCCGCAGGA 
90 68 
18S rRNA AY623831 TCGATGCTCTTAGCTGAGTGTCC 
GTAGTTTCATGGATGCCGCAGGA 
125 58 
A2AR NM_001003278 GGTCCTCACTCAGAGCTCCATCTT 
GTGCCAGTCACCAAGCCATTGTA 
102 66 
GHSR NM_001099945 GGCCTGCTCCGACCTGCTCATCTT 
GCAGCCCTCGCTCACGAACTGGAA 
124 66 
GHRL NM_001003052 CTGCTGCTCTTCAGTGTGCTC 
GCGGCTTCTTGGACTCCTTTC 
106 70 
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